Helpline
Speak to a registered nurse.
Call the Beating Bowel Cancer Helpline
(9-5:30 Mon - Thu, 9-4 Fri)

020 8973 0011

or email nurse@beatingbowelcancer.org

Pharmaceuticals statement

Policy statement – Working with pharmaceuticals companies

 

Introduction:

 

Beating Bowel Cancer receives support from a range of pharmaceutical companies with an interest in bowel cancer as part of a diverse fundraising strategy centred on people fundraising for us, people donating their own money together with support from charitable trusts and other corporate supporters.

 

The support provided by pharmaceutical companies has made an important contribution to our work on behalf of people affected by bowel cancer.

 

Beating Bowel Cancer is committed to upholding our reputation of independence, impartiality and transparency in all that we do.

 

We recognise the importance of working collaboratively with all stakeholders to ensure we do our best to meet the needs of bowel cancer patients and their families. However, the views of the charity are always reached independently and are based on informed and balanced evidence. We are governed by a Board of Trustees that sets the strategy, agrees objectives and approves plans to deliver what we set out to do. We also have a Medical Advisory Board to guide our work.

 

The purpose of this policy is to provide clear guidance about Beating Bowel Cancer’s work with pharmaceutical companies.

 

Overview:

 

Beating Bowel Cancer has a history of working with a range of pharmaceutical companies that have an interest in bowel cancer. As a patient-centred organisation, our experience shows that bowel cancer patients want us to work in partnership with key players in the cancer field; from government, the Department of Health, health professionals, to corporate partners including pharmaceutical companies.

 

We believe it is important to maintain co-operative relationships with companies that manufacture and market drugs and treatments for bowel cancer patients, but under no circumstances will these companies influence our strategic direction, activities or what we say.

 

Principles:

  • No attempt is made on the part of the companies to influence our policy, direction or action either explicitly or implicitly
  • We will not accept support from a company for activities that lie outside our charity’s strategy. The strategic objectives of the charity are determined by the best interests of people affected by bowel cancer and are in line with our vision of a world where bowel cancer is beaten
  • For projects where the charity is receiving support from the pharmaceutical industry, we will, where possible, seek support from more than one company for the project
  • The high quality information materials produced by the charity will not be influenced in any way by the acceptance of sponsorship. All information produced for patients is based on the latest evidence and peer-reviewed by patients and independent medical professionals. Our materials are Information Standard accredited
  • The charity is governed by a Board of Trustees, and has a Medical Advisory Board, which gives advice on relevant medical, NHS and regulatory issues and developments and governmental initiatives
  • We recognise that our pharmaceutical company partners must follow The Association of the British Pharmaceutical Industry (ABPI) Code of Practice
  • The charity will be open, transparent and honest in response to any public or media enquiry concerning our relationship with corporate partners
  • We are committed to being open about our Trustees’ and Senior Management Team’s relationships with corporate companies. We have a Conflict of Interest policy and Trustees’ and Senior Management Team are required to declare any conflicts on a regular basis
  • Beating Bowel Cancer will detail the percentage and amount of funds received through pharmaceutical companies each year in our Annual Report.

 

Accepting financial support:

Beating Bowel Cancer will accept financial support from a company when the following conditions are met:

  1. Activities are within the charity’s strategy. The strategic objectives of the charity are determined by the best interests of people affected by bowel cancer and are in line with our vision of a world where bowel cancer is beaten
  2. There is no attempt on the part of the company to influence the charity’s strategy or activities

 

A written agreement is drawn up at the beginning of each new partnership with a company.

 

Financial information:

Further details on the pharmaceutical companies Beating Bowel Cancer works with are on the charity’s website here.

 

Beating Bowel Cancer’s income from corporate partners for the last two financial years is in the following two tables.

 

Table 1 – Funds received from corporate companies non-pharmaceuticals in 2013/14 and 2014/15.

 

We only accept funding for activities that are within our strategy and no attempt is made on the part of the companies to influence our policy, direction or action.

 

TOTAL Amount (% of total income) 2013/14
£90,176 (6%)
TOTAL
Amount (% of total income)
2014/15
£136,352 (5.8%)
Non Pharma 2013/14 Non Pharma 2014/15
John Lewis partnership £1,000 general donation Macquarie £39,550 staff Fundraising
Olympus Keymed £7,000 towards patient day L’Oreal Men Expert £10,000 Decembeard sponsorship
Sirtex Medical £4,000 towards patient day Just For Men £10,000 Decembeard sponsorship
Dulcolax (a consumer division of Boehringer Ingelheim) £10,000 general donation Shaylor Group £14,725 Staff Fundraising
Hortons’ Estate Ltd* £5,550 staff fundraising Howard Kennedy LLP £4,099 staff Fundraising
Medinet Ltd £20,000 general donation ITV £36,000 Celebrity Chase and Catchphrase. Nominated charity.
Unipart Technology Logistics (UTL)* £19,000 staff fundraising Corporate Decembeard Participants £8,847 staff fundraising
Signet International £14,000 staff fundraising Other £13,131
Benenden Health £1,000 generaldonation
Shaylor Group £3,841 staff fundraising
Findlay Park Investment Management £1,500 general donation
BioCompatibles UK Ltd £1,660 general donation
Howard Kennedy LLP £1,400 staff fundraising
Other £225

 

*Included in Community Fundraising figures in Statutory Accounts

 

Table 2 – Funds received from pharmaceutical companies in 2012/13 and 2013/14

 

We only accept funding for activities that are within our strategy and no attempt is made on the part of the companies to influence our policy, direction or action.

 

Pharma 2013/14 Pharma 2014/15
TOTAL Amount

(% of total income)

£60,195 (4%) TOTAL Amount

(% of total income)

£94,101 (4%)
Sanofi Aventis £15,000 towards our work in Scotland
£1,000 towards nurse conference
Total £16,000
Roche £40,000 towards our digital work and website
£1,000 towards Scottish Study Day
Total £41,000
Merck Serono £10,000 towards our work in Scotland
£7,500 Parliamentary Reception
£3,000 towards patient day
£1,200 towards nurse conference
Total £21,700
Sirtex £6,000 My Sirt Story work
£4,000 towards patient day
£1,000 towards nurse conference
£1,000 towards Scottish Study Day
Total £12,000
Roche £4,000 towards patient support and campaigns
£1,000 towards nurse conference
£495 honorarium
Total £5,495
Merck Serono £3,000 towards patient day
£5,000 towards Parliamentary Reception
£1,000 towards nurse conference£1,000 towards Scottish Study Day
Total £10,000
Norgine £10,000 towards nurse conference
£7,000 towards nurse folders
Total £17,000
Norgine £10,000 towards the nurse conference
£3,000 towards patient day
£4,500 towards bus pass wallet project
Total £17,500
Olympus Keymed £7,000 towards patient day
£1,000 towards nurse conference
Total £8,000
Sanofi £1,000 towards nurse conference
£1,000 towards Scottish Study Day
Total £2,000
Coloplast £1,000 towards nurse conference
Total £1,000
Other £2,601 towards patient day and nurse conference
Total £2,601

 

N.B. For 2014/15 Sirtex Medical and Olympus Keymed have now been classified as Pharma for further transparency.